138926-19-9 Ibandronate sodium monohydrate AKSci J61808
 
 
Loading Please Wait...
  J61808    
Ibandronate sodium monohydrate
, 95%
 
1-Hydroxy-3-(methylpentylamino)propylidene)bisphosphonic acid sodium




IDENTITY
CAS Number:138926-19-9
MDL Number:MFCD00912167
MF:C9H24NNaO8P2
MW:359.23
SPECIFICATIONS & PROPERTIES
Min. Purity Spec:95%
Physical Form (at 20°C):Solid
Melting Point:173-175°C
Long-Term Storage:Store long-term at 2-8°C
DOT/IATA TRANSPORT INFORMATION
Not hazardous material

BIOLOGICAL INFO
Solubility:H2O: >10 mg/mL
Application(s):Inhibits osteoclast-mediated bone resorption

REVIEW

 Ibandronic sodium dihydrate is a potent bisphosphonate drug used in the prevention and treatment of osteoporosis in post-menopausal women. It may also be used to treat hypercalcemia (elevated blood calcium levels). The action of ibandronate on bone tissue is based partly on its affinity for hydroxyapatite, which is part of the mineral matrix of bone. Nitrogen-containing bisphosphonates such as ibrandronate appear to act as analogues of isoprenoid diphosphate lipids, thereby inhibiting farnesyl pyrophosphate (FPP) synthase, an enzyme in the mevalonate pathway. Inhibition of this enzyme in osteoclasts prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are essential for the post-translational farnesylation and geranylgeranylation of small GTPase signalling proteins. This activity inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone turnover, leading to, on average, a net gain in bone mass.

REFERENCES
[1]Epstein S, Zaidi M: Biological properties and mechanism of action of ibandronate: application to the treatment of osteoporosis. Bone. 2005 Oct;37(4):433-40.
[2] Jomaa, Hassan Medicaments containing bisphosphonic acids and their derivatives for prophylaxis and treatment of autoimmune diseases and allergies Ger. Offen. (1999), DE 19828450 A1 19991230.
[3] Bauss, Frieder; Pichler, Bernhard; Turley, Bisphosphonic acid for the treatment and prevention of osteoporosis Stephen PCT Int. Appl. (2003), WO 2003095029 A1 20031120.
[4] Burckhardt P.Ibandronate in oncology.Cancer. 1997 Oct 15;80(8 Suppl):1696-8.

GLOBALLY HARMONIZED SYSTEM (GHS)

Pictograms

Signal Word
Warning

Hazard Statements
H315; H319; H335

Precautionary Statements
P261; P264; P271; P280; P302+P352; P304+P340; P305+P351+P338; P312; P321; P332+P313; P337+P313; P362; P403+P233; P405; P501


RELATED PRODUCTS
H487Ibandronate sodium monohydrate
G724Ibandronic acid

Current as of April 24, 2024


Download SDS Request COA

All products are stocked and shipped from San Francisco Bay Area, California, USA.

⚠️
All products are for research and development use only, not for any other uses, and must be handled by technically-qualified persons.

These products are explicitly not intended to be used in foods and/or cosmetics and/or drugs (human and veterinary) and/or consumer products and/or biocides and/or pesticides of any kind unless explicitly stated otherwise.

Products are not sold to individuals. We do not ship to residential addresses. Consumer orders will be cancelled without notice.

New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. Additional restrictions may apply.



CATEGORIES

 APIs and Bioactives > Bisphosphonates


PubChem